57th ASH Annual Meeting and Exposition (December 5-8, 2015): 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD¹, Darren C. Phillips, PhD²^*, Andrew J. Souers, PhD³^*, Juraj Bodo, PhD¹^*, Paul Tapang³^*, Daniel H Albert, PhD⁴^*, Lisa Durkin¹^* and Eric D. Hsi, MD⁵

¹Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute. Cleveland Clinic, Cleveland, OH
²AbbVie, Inc., North Chicago, IL
³Oncology Discovery, AbbVie, Inc., North Chicago, IL
⁴AbbVie, North Chicago, IL
⁵Laboratory Medicine, Robert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH

2747

CD30/CD16A Tandab AFM13-Induced Target Cell Lysis By NK-Cells Is Enhanced By CD137 Co-Stimulation and Blocking PD-1

Xing Zhao¹^*, Narendiran Rajasekaran, PhD²^*, Uwe Reusch, PhD³^*, Jens-Peter Marschner, MD³^*, Martin Treder³^* and Holbrook Kohrt, MD⁴

¹Center for Clinical Sciences Research Stanford, Stanford University, Stanford, CA
²Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
³Affimed GmbH, Heidelberg, Germany
⁴Stanford University, Stanford, CA

2748

Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy

Wei Chan, PhD¹^*, Thomas Theriault, PhD²^*, Ronald Levy, MD³ and James Swartz, DSc⁴^*

¹Departement of Chemical Engineering, Stanford University, Stanford, CA
²Bullet Biotechnology, Inc, Menlo Park, CA
³Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
⁴Department of Chemical Engineering and Department of Bioengineering, Stanford University, Stanford, CA

2749

Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies

Montreh Tavakkoli, MA¹, Dong H. Lee, MD¹^*, Benjamin Durham, MD, PhD²^*, Stephen S. Chung, MD³ and Christopher Y. Park, M.D., Ph.D.⁴

¹Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
²Memorial Sloan Kettering Cancer Center, New York, NY
³Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY

2750

Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy

Annika Nelde^1,2^*, Juliane S Stickel, MD²^*, Daniel Johannes Kowalewski¹^*, Oliver Olaf Wolz¹^*, Lothar Kanz, MD², Anton W. Langerak³^*, Alice F. Muggen⁴^*, Irina Bonzheim⁵^*, Falko Fend, MD⁵^*, Hans-Georg Rammensee, PhD¹^*, Stefan Stevanovic, PhD¹^* and Alexander N.R. Weber¹^*

¹Department of Immunology, Interfaculty Institute of Cell Biology, University of Tübingen, Tuebingen, Germany
²Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
³Department of Immunology, Erasmus MC Rotterdam, Rotterdam, Netherlands
⁴Department of Immunology, Erasmus MC Rotterdam, 3015 CN Rotterdam, Rotterdam, Netherlands
⁵Department of Pathology, University Hospital Tuebingen, Tuebingen, Germany

2751

Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma

Dirk Daelemans, PhD¹^*, Eline Boons¹^*, Els Vanstreels¹^*, Maarten Jacquemyn¹^*, Tatiane C Nogueira¹^*, Jasper E Neggers¹^*, Thomas Vercruysse¹^*, Joost van den Oord²^*, Sharon Tamir³^*, Michael Kauffman, MD, PhD⁴, Sharon Shacham⁴^*, Yosef Landesman, PhD³^*, Robert Snoeck¹^*, Christophe Pannecouque¹^* and Graciela Andrei¹^*

¹KU Leuven, Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium
²KU Leuven, Department of Imaging and Pathology, Translational Cell & Tissue Research, Rega Institute for Medical Research, Leuven, Belgium
³Karyopharm Therapeutics Inc., Newton, MA
⁴Karyopharm Therapeutics, Inc, Newton, MA

2752

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Kerry A. Rogers, MD¹, Dalia El-Gamal, PhD², Harrington K. Bonnie, DVM³^*, Hing A. Zachary, BS⁴^*, Goettl M. Virginia, DVM, PhD¹^*, Mantel Rose¹^*, Lisa L. Smith, MS²^*, Lianbo Yu, PhD⁵^*, Amy J. Johnson, PhD², John C. Byrd, MD², Rosa Lapalombella, PhD² and Jennifer A. Woyach, MD²

¹Division of Hematology, The Ohio State University, Columbus, OH
²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
³Department of Veterinary Biosciences, The Ohio State University, Columbus, OH
⁴Physician Scientist Training Program, The Ohio State University, Columbus, OH
⁵Center for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH

2753

The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach

Frank C. Passero Jr., MD¹^*, Ravi Dashnamoorthy, PhD², Afshin Beheshti, PhD²^*, Lynn Hlatky, PhD³^*, Nassera Abermil, MS, PharmD³^*, Michael E Coyle, MD¹, Jaya Sharma, MD, MBBS¹ and Andrew M. Evens, DO, MSc⁴

¹Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
²Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA
³Tufts Medical Center, Boston
⁴Tufts Medical Center Cancer Center, Boston, MA

2754

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Aneel Paulus, MD, MS¹, Kasyapa S. Chitta, PhD¹, Sharoon Akhtar, MPhil²^*, Hassan Yousaf³^*, Davitte Cogen³^*, Shireen Vali⁴^*, Ansu Kumar⁵^*, Neeraj Kumar Singh⁵^*, Taher Abbasi⁴^*, James M. Foran, MD⁶, Candido E. Rivera, MD⁷, Taimur Sher, MD⁸^*, Vivek Roy, MD⁹, Sikander Ailawadhi, MD¹⁰ and Asher Alban Chanan-Khan, MD¹⁰

¹Cancer Biology, Mayo Clinic, Jacksonville, FL
²Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
³Mayo Clinic, Jacksonville, FL
⁴Cellworks Research India Ltd., Bangalore, India
⁵Cellworks Group, Inc., San Jose, CA
⁶Mayo Clinic Cancer Center, Jacksonville, FL
⁷Hematology/Oncology, Mayo Clinic, Jacksonville, FL
⁸Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL
⁹Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL
¹⁰Division of Hematology & Oncology, Mayo Clinic, Jacksonville, FL

2755

Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome

Weiyun Ai, MD, PhD¹, Chen-Yen Yang, Ph.D.²^*, Razan Faraj²^*, Taha Rakhshandhroo, BSc³^*, Shervin Afghani, BSc²^*, Laura Pincus, MD²^*, Sourav Bandyopadhyay, PhD²^* and Frank McCormick, PhD, FRS⁴^*

¹Department of Medicine-Hematology/Oncology, University of California at San Francisco, San Francisco, CA
²UCSF, San Francisco, CA
³University of California, San Diego, San Diego
⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

2756

Scavenger Receptor Type B1 Is Essential for High Density Lipoprotein Nanoparticle Induced B-Cell Lymphoma Cell Death

Jonathan Scott Rink, Ph.D.¹^*, Shuo Yang²^*, Osman Cen³^*, Fei Ying⁴^*, Young Kwang Chae, MD, MPH³, Denise Scholtens³^*, Jonathan Moreira, MD⁵^*, Amy Chadburn, MD⁶, Leo I. Gordon, MD⁴ and Colby Shad Thaxton³^*

¹Department of Urology, Northwestern University, Chicago, IL
²Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago
³Northwestern University, Chicago, IL
⁴Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, IL
⁵Department of Medicine, Northwestern University - Feinberg School of Medicine, Chicago, IL
⁶Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

2757

Dual Targeting of NOXA/MCL-1 Synergistically Induces Cell Death in Mantle Cell Lymphoma (MCL) Cells

Elisabeth Höring¹^*, German Ott, MD²^*, Christine Bayha³^*, Kleih Markus³^*, Matthias C. Voehringer, MD⁴, Heiko van Der Kuip³^* and Walter E. Aulitzky, MD⁵

¹Robert Bosch Hospital, Stuttgart, Germany
²Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
³IKP Stuttgart, Stuttgart, Germany
⁴Robert Bosch Kramkenhaus, Onkologie, Stuttgart, Germany
⁵Robert-Bosch-Krankenhaus, Stuttgart, Germany

2758

Preclinical Results Supporting Therapeutic Development of Mrg-106, an Oligonucleotide Inhibitor of Mir-155, in CTCL

Anita G Seto, PhD^*, Xuan T Beatty, BS^*, Linda A Pestano, PhD^*, Brent A Dickinson, BA^*, Marshelle S Warren, MD^*, David M Rodman, MD^* and Aimee L Jackson, PhD^*

miRagen Therapeutics, Boulder, CO

2759

Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts

Ran Wu, Ph.D.¹^*, Sheng Guo¹^*, Jie Cai, PhD²^*, Xuesong Huang¹^*, Jie Yang¹^*, Jean-Pierre Wery¹^* and Henry Qi-xiang Li, PhD¹

¹Crown Bioscience, Santa Clara
²Crown Bioscience, Santa Clara, CA

2760

Foxo 3a Signaling Mediates Apoptosis in Lymphoma Cells By the Diterpenoid Lactone Andrographolide (Andro), the Active Component of Andrographis Paniculata

Shuo Yang¹^*, Bo Ding²^*, Fei Ying³^*, Jana Svetlichnaya²^*, Austin Tom³^*, Sheila Prachand⁴^*, Yanzhuang Wang⁵^* and Leo I Gordon, MD, FACP⁶

¹Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago
²Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago
³Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, IL
⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, IL
⁵University of Michigan, Ann Arbor, MI
⁶Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

2761

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Juan J Gu, PhD¹^*, Qunling Zhang, MD, PhD^1,2^*, Cory Mavis, MSc¹^*, Myron S. Czuczman, MD^1,3 and Francisco J. Hernandez-Ilizaliturri, MD¹

¹Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY
²Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
³Celegene, Smmit, NJ

2762

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

John M. Timmerman, MD¹, Kristopher K Steward, PhD^2,3^*, Reiko E Yamada⁴^*, Patricia A Young, MD¹^*, Dena M. Minning, MD, PhD³^*, Raj K Sachdev, PhD^2,3^*, Michael J Gresser, PhD^2,3^*, Sanjay D Khare, PhD^2,3^* and Sherie L Morrison, PhD⁴^*

¹Division of Hematology & Oncology, University of California, Los Angeles, Los Angeles, CA
²ImmunGene, Inc., Camarillo, CA
³Valor Biotherapeutics, LLC, Dallas, TX
⁴University of California, Los Angeles, Los Angeles, CA

2763

In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL

Xing Zhao¹^*, Narendiran Rajasekaran, PhD²^*, Uwe Reusch, PhD³^*, Michael Weichel³^*, Kristina Ellwanger³^*, Jens-Peter Marschner, MD³^*, Martin Treder³^* and Holbrook Kohrt, MD⁴

See more of: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH